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Sir,
Spastic paraplegia type 4 (SPG4) is caused by mutations
in the SPAST gene, and is the most common form of auto-
somal dominantly inherited pure hereditary spastic paraple-
gia (HSP) worldwide (Hazan et al., 1999; Salinas et al.,
2008; Finsterer et al., 2012; Dong et al., 2018; Koh
et al., 2018; Parodi et al., 2018). Age of onset and severity
of SPG4 are known to be highly variable. In a recent issue
of Brain, Parodi et al. (2018) described an impressive series
of 842 patients with SPG4. They found that the mutation
type and the patient’s sex modified the age of onset and
disease severity. We have carefully read their paper, with
specific interest in the variable phenotype of SPG4 and the
mode of inheritance. The authors reported that most of the
patients had a positive family history; only 5.7% of all
cases occurred sporadically, similar to all large (population)
studies on SPG4. Parodi et al. (2018) did not explicitly
mention whether the sporadic cases in their cohort were
due to de novo SPAST mutations. In general, the identifica-
tion of sporadic patients with SPG4 is attributed to
common mechanisms like incomplete penetrance, somatic
mosaicism, non-paternity, and inadequate clinical assess-
ment of the parents. Altogether, true de novo occurrence
of SPAST mutations, i.e. where both parents of the patient
are proven not to have the mutation in lymphocytes,
appears rare and has—to our knowledge—never been stu-
died separately.
Confronted with the unanticipated complex phenotypes
of the first young children that we recently diagnosed with
de novo SPAST mutations (see below) and the lack of
knowledge on the topic, we thoroughly reviewed the litera-
ture using Pubmed, searching for papers using the terms
‘SPG4’, ‘SPAST’, ‘spastin’, and ‘hereditary spastic paraple-
gia’. Reference lists were screened for additional papers. All
papers were then searched for the description of cases with
sporadic HSP in the abstract and the results and discussion
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sections, assuming that cases with de novo mutations
would be identified by this strategy. Additionally, every
paper was also screened by an electronic search for the
word ‘novo’ in the pdf file of the paper. We found that,
since the discovery of the SPAST gene (Hazan et al., 1999),
a large number of papers has been published on the clinical
and molecular features of SPG4, including many case
reports (not all included in the reference list) but also
numerous large studies on selected cohorts of hundreds of
patients with familial and isolated forms of HSP from all
different parts of the world (Fonknechten et al., 2000;
Crippa et al., 2006; Depienne et al., 2006; Magariello
et al., 2006, 2010; Salinas et al., 2008; Shoukier et al.,
2009; De Bot et al., 2010; Finsterer et al., 2012; Elert-
Dobkowska et al., 2015; Park et al., 2015; Balicza et al.,
2016; Chrestian et al., 2016; Me´sza´rosova´ et al., 2016;
Burguez et al., 2017; Dong et al., 2018; Koh et al., 2018;
Parodi et al., 2018). From the literature, we were able to
identify only 14 patients who were reported to have true de
novo SPAST mutations (Table 1) (Crippa et al., 2006; Blair
et al., 2007; Depienne et al., 2007; Battini et al., 2011;
Aulitzky et al., 2014; Elert-Dobkowska et al., 2015;
Me´sza´rosova´ et al., 2016; Polymeris et al., 2016; Burguez
et al., 2017; Gillespie et al., 2018). Interestingly, all of these
patients suffered from pure HSP. Six of 14 patients were
identified in studies that had pure HSP as an inclusion
criterion, which may partly explain the absence of diver-
gent phenotypes in the literature. Disease onset was (far)
below 10 years in nine patients (Patients 2, 5, 8–12 and 14)
and after 25 years in four patients (Patients 1, 3, 7 and 13).
Of note, Patient 6 was an asymptomatic mother with a
somatic mosaicism for a SPAST mutation and three chil-
dren affected with SPG4.
After this literature study, we searched the exome data-
base of the Department of Human Genetics of the
Radboud University Medical Centre for other patients in
whom de novo mutations in the SPAST gene had been
identified. In all cases mutation analysis of both parents
had been performed and found to be negative. Referring
clinicians were asked to contribute to this study by sharing
Table 1 Patients with de novo SPAST mutations reported in the literature
Patient Paper Case Mutation
(cDNA)
Protein
change
Parents
tested
negative
Remark
1 Crippa, 2006 HSP4, II:2 c.1216 A4G p.Ile406Val Yes This male (disease onset 30 years, mild HSP) had two
daughters with early onset HSP (both at 2 years). The
daughters, but not the father carried the proposed
modifier variant c.131C4T (p.Ser44Leu) in addition
to c.1216 A4G .
2 Blair, 2007 II-3 c.1537G4A p.Gly471Asp Yes Family with pure HSP. Female, onset in infancy, long
follow-up; wheelchair dependency from age 48 years;
has daughter and son with pure HSP too, both still
able to walk at ages 26 and 24, respectively.
3 Depienne, 2007 1 c.1684C4T p.Arg562X Not
applicable
Family with pure HSP. Somatic mosaicism in the grand-
father led to spastic diplegia from 55 onwards; his
daughter had disease onset at 18, his grandson at 5.
4 Battini, 2011 8 c.1238C4T p.Ser413Leu Yes Age at onset 3 years. Pure HSP (= inclusion criterion).
5 Battini, 2011 9 c.1360G4A p.Glu454Lys Yes Age at onset 2 years. Pure HSP (= inclusion criterion).
6 Aulitzky, 2014 I.2 c.1837G4C p.Asp613His Not
applicable
Asymptomatic mother of three affected children (age
not given); low grade somatic mosaicism for the var-
iant was shown in blood cells.
7 Elert, 2015 S38 c.1246–4T4C
and 1246–2delA
p.Val416fs Yes Age at onset 28, pure HSP.
8 Me´sza´rosova´,
2016
29 c.1303C4A p.Pro435Thr Yes Childhood onset. Pure HSP (= inclusion criterion).
9 Me´sza´rosova´,
2016
33 c.1413 + 6T4C Exon 11 skipped Yes Childhood onset. Pure HSP (= inclusion criterion from
study).
10 Polymeris,
2016
9 c.1636G4A p.Gly546Arg Yes Female, age at onset 1.5. Pure HSP (= inclusion
criterion).
11 Polymeris, 2016 15 c.1496G4A p.Arg499His Yes Male, age at onset 1.5. Pure HSP (= inclusion criterion).
12 Burguez, 2017 HSP18 c.1273G4C p.Ala425Pro Yes Father (age 28) with pure HSP (including mild dysarthria
and mild intellectual disability); has three sons with
pure HSP; age at onset in father and three sons first
year of life.
13 Gillespie, 2018 1 c.1496G4A p.Arg499His Yes Female, age at onset 52 years, spastic paraplegia with
intellectual decline in first decade of life (follow-up
until 13 years).
14 Gillespie, 2018 2 c.1496G4A p.Arg499His Yes Female, age at onset at the end of the first year of life,
spastic diplegia with mild global developmental delay
(follow-up until 5 years).
e31 | BRAIN 2019: 142; 1–5 Letter to the Editor
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/7/e31/5510130 by R
adboud U
niversity N
ijm
egen user on 14 April 2020
T
a
b
le
2
C
li
n
ic
a
l
a
n
d
m
o
le
c
u
la
r
c
h
a
ra
c
te
ri
st
ic
s
o
f
1
3
D
u
tc
h
p
a
ti
e
n
ts
w
it
h
S
P
G
4
c
a
u
se
d
b
y
d
e
n
o
vo
S
P
A
S
T
m
u
ta
ti
o
n
s
ID
S
e
x
,
a
g
e
a
A
A
O
(A
A
M
D
)b
,c
,
y
M
u
ta
ti
o
n
a
n
d
p
ro
te
in
c
h
a
n
g
e
P
re
se
n
ti
n
g
sy
m
p
to
m
s
a
n
d
si
g
n
s,
a
n
d
d
is
e
a
se
c
o
u
rs
e
1
F,
2
6
6
(1
8
)
c.
1
4
9
6
G
4
A
M
ild
ly
d
e
la
ye
d
gr
o
ss
m
o
to
r
d
e
ve
lo
p
m
e
n
t;
fi
rs
t
m
e
d
ic
al
e
va
lu
at
io
n
at
6
y
(s
p
as
ti
c
d
ip
le
gi
a)
.
C
h
ild
h
o
o
d
o
n
se
t,
cl
as
si
c
p
u
re
H
SP
w
it
h
h
ar
d
ly
an
y
p
ro
gr
e
ss
io
n
.
p
.A
rg
4
9
9
H
is
d
,e
2
i
F,
2
2
5
2
(1
9
)
c.
1
4
9
6
G
4
A
D
e
la
ye
d
gr
o
ss
m
o
to
r
d
ev
e
lo
p
m
e
n
t
an
d
sp
as
ti
c
d
ip
le
gi
a.
B
e
st
m
o
to
r
ac
h
ie
ve
m
e
n
t
w
as
w
al
k
in
g
w
it
h
su
p
p
o
rt
(2
y)
,
b
u
t
sh
e
n
e
ve
r
re
ac
h
e
d
n
o
rm
al
si
tt
in
g
b
al
an
ce
w
it
h
o
u
t
su
p
p
o
rt
;
in
it
ia
l
co
gn
it
iv
e
fu
n
ct
io
n
s
an
d
fu
n
ct
io
n
s
o
f
u
p
p
e
r
e
x
tr
e
m
it
ie
s
ap
p
e
ar
e
d
n
o
rm
al
.
St
ar
ti
n
g
in
ch
ild
h
o
o
d
:
gr
ad
u
al
lo
ss
o
f
m
o
to
r
an
d
co
gn
it
iv
e
fu
n
ct
io
n
s,
le
ad
in
g
to
w
h
e
e
lc
h
ai
r
d
e
p
e
n
d
e
n
cy
(8
y)
,
ga
st
ro
st
o
m
y
fr
o
m
ag
e
1
5
,
gr
ad
u
al
lo
ss
o
f
sp
e
e
ch
fr
o
m
ag
e
1
2
o
n
,
an
d
u
se
o
f
e
ye
-t
ra
ck
in
g
sy
st
e
m
fo
r
co
m
m
u
n
ic
at
io
n
(1
9
y)
:
at
la
st
vi
si
t:
o
n
ly
p
ro
d
u
ci
n
g
so
u
n
d
s,
a
fe
w
w
o
rd
s
an
d
se
ve
re
d
ro
o
lin
g.
E
p
ile
p
sy
:
th
re
e
ge
n
e
ra
liz
e
d
se
iz
u
re
s
w
it
h
sp
o
n
ta
n
e
o
u
s
re
co
ve
ry
(1
7
y)
.
P
ro
m
in
e
n
t
si
gn
s:
te
tr
ap
le
gi
a,
n
o
h
e
ad
co
n
tr
o
l,
w
it
h
ge
n
e
ra
liz
e
d
p
ai
n
,
an
d
la
ck
o
f
e
n
e
rg
y/
fa
ti
gu
e
.
p
.A
rg
4
9
9
H
is
d
3
F,
2
1
5
2
(1
4
)
c.
1
7
7
5
T
4
A
D
e
la
ye
d
gr
o
ss
m
o
to
r
d
ev
e
lo
p
m
e
n
t
an
d
sp
as
ti
c
d
ip
le
gi
a.
B
e
st
m
o
to
r
ac
h
ie
ve
m
e
n
t
w
as
w
al
k
in
g
w
it
h
ai
d
s
(3
y)
.
W
h
e
e
l-
ch
ai
r
b
o
u
n
d
at
7
–
8
y,
b
u
t
o
th
e
rw
is
e
d
e
ve
lo
p
e
d
n
o
rm
al
ly
.
p
.Il
e
5
9
2
Ly
sd
4
i
F,
1
7
1
m
o
(1
3
)
c.
1
4
9
6
G
4
A
M
o
to
r
ab
n
o
rm
al
it
ie
s
in
th
e
fi
rs
t
ye
ar
(h
yp
o
to
n
ia
,
ch
an
gi
n
g
to
hy
p
e
rt
o
n
ia
in
fi
rs
t
ye
ar
).
D
ev
e
lo
p
e
d
ve
ry
sl
o
w
ly
:
le
ar
n
e
d
to
si
t
w
it
h
su
p
p
o
rt
(4
y)
an
d
to
st
an
d
w
it
h
su
p
p
o
rt
,
b
u
t
lo
st
th
is
at
6
y
an
d
th
e
n
b
e
ca
m
e
co
m
p
le
te
ly
w
h
e
e
lc
h
ai
r
b
o
u
n
d
.
A
rm
fu
n
ct
io
n
s
w
e
re
re
la
ti
ve
ly
sp
ar
e
d
d
u
ri
n
g
ch
ild
h
o
o
d
,
b
u
t
th
e
n
d
e
te
ri
o
ra
te
d
u
n
ti
l
al
l
fu
n
ct
io
n
s
w
e
re
lo
st
(1
1
y)
.
In
te
lle
ct
u
al
d
is
ab
ili
ty
.
O
ra
l
m
o
to
r
an
d
sp
e
e
ch
:
ab
le
to
sp
e
ak
sh
o
rt
se
n
te
n
ce
s
b
u
t
lo
st
th
is
at
5
–
6
y;
cu
rr
e
n
t
co
m
m
u
n
ic
at
io
n
w
it
h
e
ye
-t
ra
ck
in
g
sy
st
e
m
,
ca
n
o
n
ly
p
ro
d
u
ce
a
fe
w
so
u
n
d
s;
ga
st
ro
st
o
m
y
fr
o
m
th
e
ag
e
o
f
9
y;
se
ve
re
d
ro
o
lin
g.
E
p
ile
p
sy
:
fe
b
ri
le
se
iz
u
re
at
ag
e
s
1
an
d
3
y.
P
ro
m
in
e
n
t
si
gn
s:
te
tr
ap
le
gi
a,
w
it
h
ge
n
e
ra
liz
e
d
p
ai
n
,
la
ck
o
f
e
n
e
rg
y/
fa
ti
gu
e
,
sc
o
lio
si
s
an
d
a
se
ve
re
h
e
ad
d
ro
p
.
U
ri
n
ar
y
an
d
fa
e
ca
l
in
co
n
ti
n
e
n
ce
.
p
.A
rg
4
9
9
H
is
d
5
i
M
,1
5
1
m
o
(2
)
c.
1
4
9
6
G
4
A
M
o
to
r
ab
n
o
rm
al
it
ie
s
(h
yp
e
rt
o
n
ia
)
fr
o
m
fi
rs
t
w
e
e
k
s
o
f
ag
e
.
L
e
ar
n
e
d
to
w
al
k
,
m
ax
1
0
m
,
w
it
h
ai
d
s
(3
y)
.
Se
ve
re
ge
n
e
ra
liz
e
d
an
d
m
ix
e
d
sp
as
ti
c-
d
ys
to
n
ic
m
o
ve
m
e
n
t
d
is
o
rd
e
r,
tr
e
at
e
d
w
it
h
o
ra
l
m
e
d
ic
at
io
n
,
lo
ca
l
b
o
tu
lin
to
x
in
in
je
ct
io
n
s,
in
tr
at
h
e
ca
l
b
ac
lo
fe
n
(f
ro
m
6
y)
,
an
d
se
le
ct
iv
e
d
o
rs
al
rh
iz
o
to
m
y
(a
t
1
0
y)
.
D
ys
to
n
ia
w
as
re
m
ar
k
ab
ly
se
ve
re
.
A
rm
s
w
e
re
e
q
u
al
ly
af
fe
ct
e
d
as
le
gs
.
IQ
co
u
ld
n
o
t
b
e
te
st
e
d
b
e
ca
u
se
o
f
m
o
to
r
im
p
ai
rm
e
n
t.
W
as
ab
le
to
sp
e
ak
sh
o
rt
se
n
te
n
ce
s
b
u
t
h
as
lo
st
th
is
;
ac
tu
al
co
m
m
u
n
ic
at
io
n
w
it
h
e
ye
-t
ra
ck
in
g
sy
st
e
m
;
fu
lly
d
e
p
e
n
d
e
n
t
o
n
ga
st
ro
st
o
m
y.
Se
ve
re
sc
o
lio
si
s.
U
ri
n
ar
y
in
co
n
ti
n
e
n
ce
.
p
.A
rg
4
9
9
H
is
d
6
i
M
,1
3
5
2
(2
)
c.
1
4
9
6
G
4
A
D
e
la
ye
d
gr
o
ss
m
o
to
r
d
e
ve
lo
p
m
e
n
t
an
d
sp
as
ti
c
d
ip
le
gi
a.
L
e
ar
n
e
d
to
st
an
d
w
it
h
su
p
p
o
rt
(1
y)
b
u
t
n
e
ve
r
st
o
o
d
o
r
w
al
ke
d
in
d
e
p
e
n
d
e
n
tl
y;
w
al
ke
d
w
it
h
ai
d
s
u
n
ti
l
6
y,
th
e
n
b
e
ca
m
e
w
h
e
e
lc
h
ai
r-
b
o
u
n
d
w
it
h
h
e
ad
su
p
p
o
rt
.
In
te
lli
ge
n
ce
ap
p
e
ar
ed
n
o
rm
al
d
u
ri
n
g
in
fa
n
cy
an
d
e
ar
ly
ch
ild
h
o
o
d
b
u
t
th
e
n
an
e
ar
ly
‘c
e
ili
n
g
e
ff
e
ct
’
ap
p
e
ar
e
d
to
o
cc
u
r
fr
o
m
th
e
ag
e
o
f
6
y.
Sp
e
e
ch
w
as
n
o
rm
al
u
n
ti
l
4
y,
th
e
re
af
te
r
gr
ad
u
al
ly
b
e
ca
m
e
sl
o
w
e
r
an
d
d
ys
ar
th
ri
c.
P
ro
m
in
e
n
t
sy
m
p
to
m
:
la
ck
o
f
e
n
e
rg
y/
fa
ti
gu
e
.
p
.A
rg
4
9
9
H
is
d
7
i
M
,1
2
5
2
(1
1
)
c.
1
3
2
6
A
4
T
Fi
rs
t
ye
ar
re
la
ti
ve
ly
u
n
re
m
ar
k
ab
le
;
st
an
d
in
g
w
it
h
su
p
p
o
rt
(1
4
m
o
),
w
al
k
in
g
w
it
h
su
p
p
o
rt
(1
8
m
o
).
H
o
w
e
ve
r,
n
ev
e
r
st
o
o
d
o
r
w
al
ke
d
in
d
e
p
e
n
d
e
n
tl
y;
w
al
ke
d
w
it
h
ai
d
s
u
n
ti
l
4
y,
th
e
n
ra
p
id
ly
b
e
ca
m
e
sp
as
ti
c
d
ip
le
gi
c
an
d
d
e
p
e
n
d
e
n
t
o
n
a
w
h
e
e
lc
h
ai
r
w
it
h
h
e
ad
su
p
p
o
rt
(7
y)
.
L
e
ar
n
e
d
to
w
ri
te
(7
y)
b
u
t
h
an
d
fu
n
ct
io
n
d
e
te
ri
o
ra
te
d
,
st
ill
so
m
e
h
an
d
fu
n
ct
io
n
at
ag
e
1
0
y.
In
it
ia
l
IQ
w
as
av
e
ra
ge
,
b
u
t
gr
ad
u
al
d
e
te
ri
o
ra
ti
o
n
o
cc
u
rr
e
d
(l
as
t
IQ
6
9
at
ag
e
8
y)
.
Sp
e
e
ch
sl
o
w
ly
d
e
te
ri
o
ra
te
d
fr
o
m
7
y,
b
u
t
is
st
ill
ab
le
to
sp
e
ak
at
ag
e
1
0
;
h
o
w
e
ve
r,
m
u
ch
sl
o
w
e
r.
E
p
ile
p
sy
:
fe
b
ri
le
se
iz
u
re
at
ag
e
2
an
d
tw
o
ge
n
e
ra
liz
e
d
se
iz
u
re
s
at
ag
e
9
,
tr
e
at
e
d
w
it
h
le
ve
ti
ra
ce
ta
m
.
U
ri
n
ar
y
an
d
fa
e
ca
l
in
co
n
ti
n
e
n
ce
(9
y)
,
an
d
st
ar
ti
n
g
d
ys
p
h
ag
ia
(1
0
y)
.
P
ro
m
in
e
n
t
si
gn
s:
la
ck
o
f
e
n
e
rg
y/
fa
ti
gu
e
.
p
.G
lu
4
4
2
A
sp
f,
g
8
F,
1
2
2
.5
(5
)
c.
1
2
2
6
C
4
T
M
ild
ly
d
e
la
ye
d
gr
o
ss
m
o
to
r
d
e
ve
lo
p
m
e
n
t,
w
it
h
u
n
su
p
p
o
rt
e
d
si
tt
in
g
at
1
2
m
o
an
d
in
d
e
p
e
n
d
e
n
t
w
al
k
in
g
at
2
1
m
o
.
Sp
as
ti
c
d
ip
le
gi
a
d
ia
gn
o
se
d
at
ag
e
2
.5
y.
U
se
s
w
h
e
e
lc
h
ai
r
fo
r
lo
n
g
d
is
ta
n
ce
s,
o
th
e
rw
is
e
fa
vo
u
ra
b
le
d
e
ve
lo
p
m
e
n
t.
IQ
(b
as
e
d
o
n
sc
h
o
o
l
p
e
rf
o
rm
an
ce
)
ab
o
ve
av
e
ra
ge
.
p
.A
la
4
0
9
V
al
f,
h
9
i
F,
1
1
5
2
(3
)
c.
1
4
9
6
G
4
A
A
t
1
y
9
m
o
fi
rs
t
vi
si
t
to
p
ae
d
ia
tr
ic
ia
n
b
e
ca
u
se
o
f
n
o
t
w
al
k
in
g
in
d
e
p
e
n
d
e
n
tl
y
an
d
sa
yi
n
g
n
o
th
in
g
e
ls
e
th
an
‘m
am
’
an
d
‘d
ad
’.
Sp
as
ti
c
p
ar
ap
le
gi
a
w
as
d
ia
gn
o
se
d
.
D
id
n
o
t
d
ev
e
lo
p
fr
o
m
th
at
m
o
m
e
n
t,
an
d
m
o
to
r
p
e
rf
o
rm
an
ce
,
sp
e
e
ch
an
d
sw
al
lo
w
in
g
p
ro
gr
e
ss
iv
e
ly
w
o
rs
e
n
e
d
fr
o
m
th
e
th
ir
d
ye
ar
o
f
lif
e
.
Sh
e
w
as
fi
tt
e
d
w
it
h
a
ga
st
o
st
o
m
y
(3
y)
an
d
b
e
ca
m
e
w
h
e
e
lc
h
ai
r-
b
o
u
n
d
(6
y)
.
p
.A
rg
4
9
9
H
is
d
1
0
F,
1
0
5
2
(3
)
c.
1
1
6
9
T
4
G
C
H
D
(s
u
rg
e
ry
at
ag
e
8
m
o
).
C
o
m
p
la
in
ts
re
ga
rd
in
g
gr
o
ss
m
o
to
r
d
e
ve
lo
p
m
e
n
t
an
d
st
iff
le
gs
w
e
re
in
it
ia
lly
at
tr
ib
u
te
d
to
C
H
D
;fi
rs
t
re
fe
rr
al
to
p
ae
d
ia
tr
ic
n
e
u
ro
lo
gy
fo
r
e
va
lu
at
io
n
at
2
y
6
m
o
.S
p
as
ti
c
d
ip
le
gi
a.
L
e
ar
n
e
d
to
w
al
k
in
d
e
p
e
n
d
e
n
tl
y
at
3
,
b
u
t
p
re
fe
rs
ro
lla
to
r.
U
se
s
a
w
h
e
e
lc
h
ai
r
fo
r
lo
n
g
d
is
ta
n
ce
s,
o
th
e
rw
is
e
n
o
rm
al
d
ev
e
lo
p
m
e
n
t.
p
.M
e
t3
9
0
A
rg
f
1
1
F,
6
5
2
(2
)
c.
1
0
7
2
G
4
T
D
e
la
ye
d
gr
o
ss
m
o
to
r
d
ev
e
lo
p
m
e
n
t
an
d
sp
as
ti
c
d
ip
le
gi
a:
si
tt
in
g
5
1
2
m
o
,
1
5
m
o
st
an
d
in
g.
L
e
ar
n
e
d
to
w
al
k
w
it
h
su
p
p
o
rt
(3
y)
.
O
th
e
rw
is
e
n
o
rm
al
d
ev
el
o
p
m
e
n
t.
U
n
d
e
rw
e
n
t
se
le
ct
iv
e
d
o
rs
al
rh
iz
o
to
m
y
at
ag
e
5
.
W
al
k
s
w
it
h
ro
lla
to
r.
p
.V
al
3
5
8
P
h
e
f
1
2
i
M
,5
5
2
(2
)
c.
1
3
6
0
G
4
A
D
iffi
cu
lt
to
cl
as
si
fy
d
e
ve
lo
p
m
e
n
ta
ld
is
o
rd
e
r.
A
t
2
y:
si
ts
b
u
t
ca
n
n
o
t
si
t
fr
o
m
su
p
in
e
;d
o
e
s
n
o
t
ro
ll
o
ve
r,
d
o
e
s
n
o
t
st
an
d
,d
o
e
s
n
o
t
sp
e
ak
.A
rm
s
w
it
h
so
m
e
d
ys
to
n
ic
p
o
st
u
ri
n
g;
ax
ia
lh
yp
o
to
n
ia
;l
e
gs
se
ve
re
ly
in
vo
lv
e
d
(a
p
p
e
ar
sp
as
ti
c,
b
u
t
w
it
h
at
yp
ic
al
p
o
st
u
ri
n
g,
re
m
ar
k
ab
le
fl
o
p
p
in
e
ss
w
it
h
ra
p
id
in
cr
e
as
e
o
f
m
u
sc
le
to
n
e
w
h
e
n
m
an
ip
u
la
ti
n
g;
in
cr
e
as
e
d
te
n
d
o
n
re
fl
e
x
e
s
b
u
t
w
it
h
o
u
t
cl
o
n
u
s;
b
ila
te
ra
l
st
ri
at
al
to
e
s
o
r
sp
o
n
ta
n
e
o
u
s
B
ab
in
sk
i
si
gn
s)
.
A
t
2
.5
y:
ca
n
st
an
d
b
u
t
n
o
t
w
al
k
.
A
t
5
y:
fa
ce
n
o
rm
al
,
ar
m
s
o
n
ly
m
ild
ly
af
fe
ct
e
d
;
le
gs
sh
o
w
sp
as
ti
c
d
ip
le
gi
a
w
it
h
in
ab
ili
ty
to
w
al
k
(u
se
s
a
w
h
e
e
lc
h
ai
r
fr
o
m
an
e
ar
ly
ag
e
).
Fl
o
p
p
in
e
ss
an
d
e
x
tr
ap
yr
am
id
al
fe
at
u
re
s
h
av
e
la
rg
e
ly
d
is
ap
p
e
ar
e
d
.S
p
e
e
ch
d
e
ve
lo
p
m
e
n
t
is
st
ill
al
m
o
st
ab
se
n
t
(s
ay
s
o
n
ly
so
m
e
si
n
gl
e
w
o
rd
s)
,d
e
sp
it
e
im
p
re
ss
io
n
o
f
n
o
rm
al
IQ
,
an
d
d
e
sp
it
e
n
e
ar
ly
n
o
rm
al
o
ra
l
m
o
to
r
fu
n
ct
io
n
s.
p
.G
lu
4
5
4
Ly
sd
,e
1
3
M
,2
5
2
(2
)
c.
1
4
8
3
G
4
C
D
e
la
ye
d
gr
o
ss
m
o
to
r
d
ev
e
lo
p
m
e
n
t
an
d
sp
as
ti
c
d
ip
le
gi
a:
u
n
ab
le
to
si
t
at
1
2
m
o
,
st
iff
n
e
ss
o
f
th
e
le
gs
.
Sp
as
ti
c
p
ar
ap
le
gi
a.
St
ill
u
n
ab
le
to
w
al
k
w
it
h
ai
d
s
at
2
y
4
m
o
;
ar
m
s
ar
e
o
n
ly
m
ild
ly
af
fe
ct
e
d
.
In
te
lli
ge
n
ce
ap
p
e
ar
s
fu
lly
n
o
rm
al
.
Sp
e
ak
s
si
n
gl
e
w
o
rd
s
at
2
y,
4
m
o
.
p
.A
la
4
9
5
P
ro
f
a
A
ge
at
3
1
D
e
ce
m
b
e
r
2
0
1
8
,
in
ye
ar
s
u
n
le
ss
o
th
e
rw
is
e
st
at
e
d
.
b
T
h
e
p
ar
e
n
ts
o
f
m
o
st
yo
u
n
g
p
at
ie
n
ts
o
n
ly
gr
ad
u
al
ly
b
e
ca
m
e
aw
ar
e
o
f
th
e
fa
ct
th
at
th
e
gr
o
ss
m
o
to
r
d
ev
e
lo
p
m
e
n
t
o
f
th
e
ir
ch
ild
re
n
p
ro
gr
e
ss
e
d
to
o
sl
o
w
ly
,
an
d
th
e
ir
le
gs
w
e
re
st
iff
;
th
e
re
fo
re
,
it
w
as
im
p
o
ss
ib
le
to
d
e
te
rm
in
e
th
e
e
x
ac
t
ag
e
at
w
h
ic
h
sy
m
p
to
m
s
o
cc
u
rr
e
d
.
Fo
r
th
at
re
as
o
n
,
w
e
d
e
ci
d
e
d
to
d
e
n
o
te
‘in
th
e
fi
rs
t
2
y
o
f
lif
e
’
h
e
re
,
in
al
l
th
e
se
ca
se
s;
o
n
ly
w
h
e
n
th
e
h
is
to
ry
w
as
e
vi
d
e
n
tl
y
d
iff
e
re
n
t,
an
d
an
ag
e
at
o
n
se
t
co
u
ld
b
e
gi
ve
n
m
o
re
p
re
ci
se
ly
,
w
e
in
d
ic
at
e
d
th
is
.
c
W
h
o
le
e
x
o
m
e
se
q
u
e
n
ci
n
g
le
d
to
th
e
m
o
le
cu
la
r
d
ia
gn
o
si
s
in
al
l
p
at
ie
n
ts
,
e
x
ce
p
t
P
at
ie
n
ts
1
,
3
,
8
an
d
9
,
in
w
h
o
m
ta
rg
e
te
d
SP
A
ST
m
u
ta
ti
o
n
an
al
ys
is
w
as
p
e
rf
o
rm
e
d
.
d
K
n
o
w
n
SP
A
ST
m
u
ta
ti
o
n
s:
c.
1
4
9
6
G
4
A
(P
ar
k
et
al
.,
2
0
1
5
);
c.
1
7
7
5
T
4
A
(P
ar
o
d
i
et
al
.,
2
0
1
8
);
c.
1
3
6
0
G
4
A
(F
o
gl
i
et
al
.,
2
0
0
9
).
e
T
h
e
p
ro
p
o
se
d
m
o
d
ifi
e
r
c.
1
3
1
C
4
T
(p
.S
e
r4
4
L
e
u
)
(S
ve
n
so
n
et
al
.,
2
0
0
4
)
w
as
o
n
ly
fo
u
n
d
in
th
e
SP
A
ST
ge
n
e
in
P
at
ie
n
ts
1
an
d
1
2
.
f N
o
ve
l
m
u
ta
ti
o
n
s:
c.
1
3
2
6
A
4
T
;
c.
1
2
2
6
C
4
T
;
c.
1
1
6
9
T
4
G
;
c.
1
0
7
2
G
4
T
;
an
d
c.
1
4
8
3
G
4
C
.
g
T
h
e
sa
m
e
co
d
o
n
is
af
fe
ct
e
d
b
y
a
k
n
o
w
n
m
u
ta
ti
o
n
,
1
3
2
4
G
4
A
,
G
lu
4
4
2
L
ys
(R
ib
ai
et
al
.,
2
0
0
8
;
P
ar
o
d
i
et
al
.,
2
0
1
8
).
h
A
lt
e
rn
at
iv
e
ly
,
c.
1
2
2
6
C
4
T
m
ay
al
so
le
ad
to
p
.A
la
4
0
9
_
T
yr
4
1
5
d
e
l.
i C
o
m
p
le
x
H
SP
.
A
A
O
=
ag
e
at
o
n
se
t;
A
A
M
D
=
ag
e
at
m
o
le
cu
la
r
d
ia
gn
o
si
s;
C
H
D
=
co
n
ge
n
it
al
h
ip
d
ys
p
la
si
a;
m
o
=
m
o
n
th
s;
y
=
ye
ar
s.
Letter to the Editor BRAIN 2019: 142; 1–5 | e31
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/7/e31/5510130 by R
adboud U
niversity N
ijm
egen user on 14 April 2020
clinical, neuroimaging and molecular data of their
patients, after having obtained informed consent of the
patient and/or the parents, in order to get a first impres-
sion of the clinical significance of the de novo occurrence
of SPAST mutations. Doing so, we identified 13 patients
(Table 2) and found that six patients (Patients 1, 3, 8, 10,
11 and 13) had pure HSP (note, Patient 13 may be too
young for final phenotyping). Contrasting this classic
phenotype in six patients, however, the other seven
patients showed an exceptional phenotype. Patients 2,
4–7, 9 and 12 suffered from a complex, generalized and
progressive motor disorder with onset in the first or
second year of life. Additionally, they almost invariably
also suffered from severe, progressive loss of cognitive
functions, loss of spoken language, and severe dysphagia
requiring tube feeding. Three of these patients also had
seizures. MRI studies in these 13 Dutch patients had been
performed at different ages, on different machines, and
following different protocols; irrespective of these disad-
vantages we could conclude that cerebral imaging gener-
ally did not show any abnormalities, neither in the
patients with pure HSP nor in the more severely affected
children.
Most of the SPAST mutations that occurred de novo in
the patients identified in the literature study (Table 1) and
our cohort (Table 2) are also present in families with multi-
ple generations with pure HSP. The common c.1496G4A
mutation was even found in nine of the 27 (33%) patients
identified with a de novo SPAST mutation; remarkably, five
of the seven Dutch patients with the complex SPG4 pheno-
type harboured this mutation. In addition to a de novo
mutation, the proposed modifier c.131C4T (p.Ser44Leu)
(Svenson et al., 2004) was found in the SPAST gene in
2 of the 13 Dutch patients, one with a pure HSP phenotype
(Patient 1) and one with a complex phenotype (Patient 12).
The low number of cases and the relative high occurrence
of c.131C4T in controls (between 1–2% in Europe;
Database ExAC, Lek et al., 2016) does not allow for any
conclusions.
We have no explanation for the fact that some SPAST
mutations can lead to pure HSP as well as to the highly
complex phenotype presented here. The SPAST mutations
that may be associated with complex SPG4 when occurring
de novo never seem to cause such a severe phenotype in
individuals from large, multi-generation SPG4 families.
This observation pleads against the presence of a simple,
independent explanation in addition to the de novo occur-
rence of the SPAST mutation, such as a genetic or environ-
mental modifier, for the existence of the complex SPG4
phenotype.
Based on all available data, only a minority of patients
with de novo SPAST mutations appear to suffer from the
complex SPG4 phenotype. The high number of patients
(22/27, 81%) with a de novo SPAST mutation and an
extremely early onset of disease, in our series (13/13) as
well as the literature (9/14), however, may point to a rela-
tionship between age of onset and the de novo occurrence
of the mutation. Of note, this observation may also simply
reflect the greater need to study parental carriership (and
thus the chance to find a de novo mutation) in paediatric
practices compared to adult neurogenetic services.
With regard to the apparent (extreme) rarity of the
complex SPG4 phenotype, it seems reasonable to
assume that the true incidence may be higher since
many paediatric cases with such a severe phenotype
may never have had SPAST mutation analyses and thus
may have been missed in the era before next generation
sequencing techniques became available. This possibility
might be illustrated by the fact that we identified most
Dutch patients in a relatively short period. Recognition
and acceptance of the complex SPG4 phenotype at the far
end of the clinical spectrum of SPG4 are the first steps
towards an appropriate diagnosis. Future studies will
hopefully contribute to the further delineation of the
complex phenotype, and the understanding of its under-
lying molecular mechanisms.
In conclusion, we recognized a complex SPG4 phenotype
with an infantile onset, complex, generalized, and progres-
sive motor disorder and severe cognitive decline and loss of
spoken language. This phenotype has never been reported
in SPG4 families, and it appears to us that only de novo
SPAST mutations can cause such a complex phenotype.
Our clinical, observational study does not allow us to
explain the remarkable findings. Nevertheless, we gladly
add our data to the recent work of Parodi et al. (2018),
and are willing to open a scientific discussion on what we
think is a new clinical SPG4 phenotype.
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